| 000 | 01527 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250513153654.0 | ||
| 264 | 0 | _c19981123 | |
| 008 | 199811s 0 0 eng d | ||
| 022 | _a0165-6147 | ||
| 024 | 7 |
_a10.1016/s0165-6147(98)01244-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEglen, R M | |
| 245 | 0 | 0 |
_a'Seeing through a glass darkly': casting light on imidazoline 'I' sites. _h[electronic resource] |
| 260 |
_bTrends in pharmacological sciences _cSep 1998 |
||
| 300 |
_a381-90 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAdrenergic alpha-Agonists _xpharmacology |
| 650 | 0 | 4 |
_aAdrenergic alpha-Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aAgmatine _xchemistry |
| 650 | 0 | 4 |
_aAllosteric Site _xdrug effects |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBinding, Competitive |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 |
_aClonidine _xchemistry |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 |
_aImidazoles _xchemistry |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 |
_aMonoamine Oxidase _xchemistry |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xpharmacology |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aHudson, A L | |
| 700 | 1 | _aKendall, D A | |
| 700 | 1 | _aNutt, D J | |
| 700 | 1 | _aMorgan, N G | |
| 700 | 1 | _aWilson, V G | |
| 700 | 1 | _aDillon, M P | |
| 773 | 0 |
_tTrends in pharmacological sciences _gvol. 19 _gno. 9 _gp. 381-90 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0165-6147(98)01244-9 _zAvailable from publisher's website |
| 999 |
_c9750562 _d9750562 |
||